2. The use of claim 1, wherein said treatment reduces left ventricular outflow obstruction in the subject.

3. Use of a compound as defined in claim 1 or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament, for treating a disease or disorder selected from the group consisting of diastolic heart failure with preserved ejection fraction, ischemic heart disease, angina pectoris, and restrictive cardiomyopathy, in a subject in need thereof.

4. Use of a compound as defined in claim 1 or a pharmaceutically acceptable salt thereof, in the manufacture of medicament for treating ~~a disease or disorder characterized by~~ left ventricular hypertrophy, in a subject in need thereof.

5. The use of claim 4, wherein ~~said disease or disorder is selected from the group consisting of~~ the subject is suffering from chronic mitral regurgitation, chronic aortic stenosis, and chronic systemic hypertension.

6. The use of claim 5, wherein said medicament is to be administered in conjunction with one or more therapies selected from the group consisting of valve repair, valve replacement, and effective antihypertensive therapy.

7. Use of a compound as defined in claim 1 or a pharmaceutically acceptable salt thereof , in the manufacture of a medicament for treating hypertrophic cardiomyopathy (HCM), in a subject in need thereof , wherein said medicament is to be administered in combination with one or more therapies that retard the progression of heart failure by down-regulating neurohormonal stimulation of the heart and attempt to prevent cardiac remodeling.

8. The use of claim 7, wherein the one or more therapies that retard the progression of heart failure by down-regulating neurohormonal stimulation of the heart and attempt to prevent cardiac remodeling are selected from the group consisting of ACE inhibitors, angiotensin receptor blockers (ARBs), β-blockers, aldosterone receptor antagonists, and neural endopeptidase inhibitors.

9. Use of a compound of claim 1 or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating hypertrophic cardiomyopathy (HCM), in a subject in need thereof, wherein said medicament is to be administered in combination with one or more therapies that improve cardiac function by stimulating cardiac contractility.